Cerlapirdine

TargetMol
Product Code: TAR-T30798
Supplier: TargetMol
CodeSizePrice
TAR-T30798-1mg1mg£130.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30798-5mg5mg£213.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30798-1mL1 mL * 10 mM (in DMSO)£238.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30798-10mg10mg£303.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30798-25mg25mg£530.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30798-50mg50mg£731.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30798-100mg100mg£978.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Cerlapirdine is a selective, potent, full antagonist of the 5-hydroxytryptamine 6 (5-HT6) receptor. Cerlapirdine is already in clinical development for the treatment of cognitive disorders related to Alzheimer's disease and schizophrenia. It works by acting as a selective 5-HT6 receptor antagonist.
CAS:
925448-93-7
Formula:
C22H23N3O3S
Molecular Weight:
409.5
Pathway:
GPCR/G Protein; Neuroscience
Purity:
0.986
SMILES:
CN(C)CCCOc1ccc2n[nH]c(c2c1)S(=O)(=O)c1cccc2ccccc12
Target:
5-HT Receptor

References

1. Tse S, Leung L, Raje S, Seymour M, Shishikura Y, Obach RS. Disposition and metabolic profiling of [(14)C]cerlapirdine using accelerator mass spectrometry. Drug Metab Dispos. 2014 Dec;42(12):2023-32. 2. Ly S, Pishdari B, Lok LL, Hajos M, Kocsis B. Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9. 3. Macauley D. American Chemical Society-239th national meeting--Investigating new therapeutic candidates:part 1. 21-25 March 2010, San Francisco, CA, USA. IDrugs. 2010 May;13(5):289-91.